Cargando…

High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy

BACKGROUND: Botulinum neurotoxin therapy (BoNT) is a powerful tool for treating many neurologic disorders. The U.S. Food and Drug Administration (FDA)-approved maximum onabotulinum toxin A (OnaA) dose is 400 units (U) per visit, but higher doses are commonly necessary, particularly when treating mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Shannon Y., Patel, Bhavana, Burns, Matthew R., Legacy, Joseph, Wagle Shukla, Aparna, Ramirez-Zamora, Adolfo, Deeb, Wissam, Malaty, Irene A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia University Libraries/Information Services 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052428/
https://www.ncbi.nlm.nih.gov/pubmed/32149014
http://dx.doi.org/10.7916/tohm.v0.749
_version_ 1783502870916628480
author Chiu, Shannon Y.
Patel, Bhavana
Burns, Matthew R.
Legacy, Joseph
Wagle Shukla, Aparna
Ramirez-Zamora, Adolfo
Deeb, Wissam
Malaty, Irene A.
author_facet Chiu, Shannon Y.
Patel, Bhavana
Burns, Matthew R.
Legacy, Joseph
Wagle Shukla, Aparna
Ramirez-Zamora, Adolfo
Deeb, Wissam
Malaty, Irene A.
author_sort Chiu, Shannon Y.
collection PubMed
description BACKGROUND: Botulinum neurotoxin therapy (BoNT) is a powerful tool for treating many neurologic disorders. The U.S. Food and Drug Administration (FDA)-approved maximum onabotulinum toxin A (OnaA) dose is 400 units (U) per visit, but higher doses are commonly necessary, particularly when treating multiple body regions. METHODS: We collected demographics, OnaA dose, body regions injected and indications, patient-reported efficacy via 7-point Clinical Global Impression Scale (CGIS), and duration of benefit. RESULTS: Sixty-eight patients were identified receiving OnaA >400 U/session. Dystonia (n = 44) and spasticity (n = 24) were the most common indications for high-dose OnaA. Mean duration of benefit was 9 weeks (standard deviation [SD] 3). More than 70% of patients self-reported “very much improved” or “much improved” at 6 month, 1 year, and last visit. No serious adverse effects were reported. DISCUSSION: The majority of patients tolerated >400 U OnaA with continued benefit. OnaA doses >400 U may be safe and effective in appropriate patients.
format Online
Article
Text
id pubmed-7052428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Columbia University Libraries/Information Services
record_format MEDLINE/PubMed
spelling pubmed-70524282020-03-06 High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy Chiu, Shannon Y. Patel, Bhavana Burns, Matthew R. Legacy, Joseph Wagle Shukla, Aparna Ramirez-Zamora, Adolfo Deeb, Wissam Malaty, Irene A. Tremor Other Hyperkinet Mov (N Y) Brief Reports BACKGROUND: Botulinum neurotoxin therapy (BoNT) is a powerful tool for treating many neurologic disorders. The U.S. Food and Drug Administration (FDA)-approved maximum onabotulinum toxin A (OnaA) dose is 400 units (U) per visit, but higher doses are commonly necessary, particularly when treating multiple body regions. METHODS: We collected demographics, OnaA dose, body regions injected and indications, patient-reported efficacy via 7-point Clinical Global Impression Scale (CGIS), and duration of benefit. RESULTS: Sixty-eight patients were identified receiving OnaA >400 U/session. Dystonia (n = 44) and spasticity (n = 24) were the most common indications for high-dose OnaA. Mean duration of benefit was 9 weeks (standard deviation [SD] 3). More than 70% of patients self-reported “very much improved” or “much improved” at 6 month, 1 year, and last visit. No serious adverse effects were reported. DISCUSSION: The majority of patients tolerated >400 U OnaA with continued benefit. OnaA doses >400 U may be safe and effective in appropriate patients. Columbia University Libraries/Information Services 2020-02-27 /pmc/articles/PMC7052428/ /pubmed/32149014 http://dx.doi.org/10.7916/tohm.v0.749 Text en © 2020 Chiu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.
spellingShingle Brief Reports
Chiu, Shannon Y.
Patel, Bhavana
Burns, Matthew R.
Legacy, Joseph
Wagle Shukla, Aparna
Ramirez-Zamora, Adolfo
Deeb, Wissam
Malaty, Irene A.
High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
title High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
title_full High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
title_fullStr High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
title_full_unstemmed High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
title_short High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
title_sort high-dose botulinum toxin therapy: safety, benefit, and endurance of efficacy
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052428/
https://www.ncbi.nlm.nih.gov/pubmed/32149014
http://dx.doi.org/10.7916/tohm.v0.749
work_keys_str_mv AT chiushannony highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT patelbhavana highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT burnsmatthewr highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT legacyjoseph highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT wagleshuklaaparna highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT ramirezzamoraadolfo highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT deebwissam highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy
AT malatyirenea highdosebotulinumtoxintherapysafetybenefitandenduranceofefficacy